Cymbalta for chronic pain
Eli Lilly submits supplemental new drug application in the second quarter for Cymbalta (duloxetine) in the management of chronic pain, the firm announces May 29. With an expected 10-month review, the drug's likely PDUFA timeframe would be February to March 2009. The drug was approved for acute and maintenance treatment of major depressive disorder Nov. 30; it is also approved for acute treatment of generalized anxiety disorder and management of diabetic peripheral neuropathic pain, all in adults 18 and older. An sNDA for use of the drug in fibromylagia is under FDA review, with an expected PDUFA data in June
You may also be interested in...
Two top officials in the US FDA’s device center are warning of delays in the agency’s review of submissions for new products that aren’t directly tied to the coronavirus pandemic.
With 12 new BTDs announced so far this year, 2021 is on pace to match the COVID-19-depressed total number of designations in 2020. Here’s a breakdown of the candidates that have received the designation.
Popular expedited review program results in a higher approval rate than the related fast track designation, but the COVID-19 era is seeing a drop in designations and a rise in complete response letters for BTD programs.